Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.62) by 1.61 percent. This is a 48.74 percent increase over losses of $(1.19) per share from the same period last year.